ReviewTranslational breast cancer research : a journal focusing on translational research in breast cancer2026
Chinese Society of Clinical Oncology breast cancer expert consensus on the diagnosis and treatment of breast cancer brain metastasis (2025).
Review in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Globally, breast cancer (BC) ranks among the most frequently diagnosed malignant tumors in women. Given the high prevalence of BC, brain metastasis (BM) arising from this malignancy are the second most frequent type among patients surpassed only by those from lung cancer. This expert consensus aims to standardize the management of BC brain metastases (BCBM) and improve patient outcomes; it serves as a practical, evidence-based guide for clinicians and allied specialists. Methods: An expert panel comprising specialists from disciplines including medical oncology, breast surgery, neurosurgery, and pathology was convened. In developing this expert consensus, the expert panel conducted a comprehensive literature review and referenced authoritative guidelines from both domestic and international sources. Results: With advancements of systemic therapies, an expanding array of medications has demonstrated efficacy against BCBM, especially among individuals with human epidermal growth factor receptor 2 (HER2)-positive BCBM. In this consensus, we systematically evaluate the following key components: clinical manifestations, imaging assessments, pathological diagnosis, treatment strategies, prognostic outcomes, follow-up and post-treatment monitoring. Conclusions: This updated consensus incorporates significant revisions across key domains-including pathological diagnosis, chemotherapy, anti-HER2 targeted therapy, and the sequencing of radiotherapy and systemic treatments-while introducing new recommendations on imaging surveillance criteria and frequency, other targeted agents, and the integration of systemic therapy with local modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.